Page last updated: 2024-11-10

harman

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

harman: a beta-carboline; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
PeganumgenusA plant genus of the family ZYGOPHYLLACEAE. HARMALINE and other ALKALOIDS, phenylpropanoids, and TRITERPENES have been found in plants of this genus.[MeSH]Nitrariaceae[no description available]
PassifloragenusA plant genus of the family Passifloraceae, order Violales, subclass Dilleniidae, class Magnoliopsida. They are vines with ornamental flowers and edible fruit.[MeSH]PassifloraceaeA plant family of the order Violales, subclass Dilleniidae, class Magnoliopsida that are herbaceous or woody vines, shrubs, and trees, mostly of warm regions. Many have tendrils in leaf axils. Leaves are alternate. Flowers have 3-5 sepals, petals and stamens. Nearly all species have seeds that bear a fleshy appendage called an aril.[MeSH]
Sickingiagenus[no description available]RubiaceaeThe Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH]
TribulusgenusA plant genus of the family ZYGOPHYLLACEAE. Members contain steroidal saponins. Ingestion by grazing animals causes PHOTOSENSITIVITY DISORDERS called geeldikkop (yellow thick head) in South Africa.[MeSH]ZygophyllaceaeA plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida which is a small family of small trees and shrubs growing in arid and warm regions.[MeSH]
BanisteriopsisgenusA plant genus of the family MALPIGHIACEAE which includes an Amazonian psychoactive plant that contains the beta-carboline harmine and N,N-dimethyltryptamine.[MeSH]MalpighiaceaeA plant family of the order Polygalales, subclass Rosidae class, Magnoliopsida that are mostly shrubs and small trees. Many of the members contain indole alkaloids.[MeSH]
Peganum harmalaspecies[no description available]Nitrariaceae[no description available]
Passiflora incarnataspecies[no description available]PassifloraceaeA plant family of the order Violales, subclass Dilleniidae, class Magnoliopsida that are herbaceous or woody vines, shrubs, and trees, mostly of warm regions. Many have tendrils in leaf axils. Leaves are alternate. Flowers have 3-5 sepals, petals and stamens. Nearly all species have seeds that bear a fleshy appendage called an aril.[MeSH]
Sickingia rubraspecies[no description available]RubiaceaeThe Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH]
Tribulus terrestrisspecies[no description available]ZygophyllaceaeA plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida which is a small family of small trees and shrubs growing in arid and warm regions.[MeSH]
Banisteriopsis caapispecies[no description available]MalpighiaceaeA plant family of the order Polygalales, subclass Rosidae class, Magnoliopsida that are mostly shrubs and small trees. Many of the members contain indole alkaloids.[MeSH]

Cross-References

ID SourceID
PubMed CID5281404
CHEMBL ID12014
CHEBI ID5623
SCHEMBL ID141723
MeSH IDM0046284

Synonyms (135)

Synonym
AC-15673
9h-pyrido(3,4-b)indole, 1-methyl-
einecs 207-642-2
nsc 54439
ccris 6419
1-methyl-9h-pyrido(3,4-b)indole
brn 0143898
HMS3267O04
BB 0254238
BRD-K12630395-003-03-8
wln: t b656 en hmj f
loturine
NSC54439 ,
1-methylnorharman
nsc-54439
1-methyl-9h-pyrid[3,4-b]indole
aribine
harmane
aribin
passiflorin
pyridobindole, l-methyl-
3-methyl-4-carboline
1-methyl-9h-pyrido[3,4-b]indole
locuturin
locuturine
1-methyl-.beta.-carboline
DIVK1C_006705
SDCCGMLS-0066938.P001
EU-0100605
SPECTRUM_001126
cas-21655-84-5
lopac-h-7258
NCGC00025022-01
NCGC00015514-01
tocris-1132
NCGC00015514-02
PRESTWICK3_000620
LOPAC0_000605
BPBIO1_000616
PRESTWICK2_000620
OPREA1_152883
BSPBIO_000560
1-methyl-9h-beta-carboline
inchi=1/c12h10n2/c1-8-12-10(6-7-13-8)9-4-2-3-5-11(9)14-12/h2-7,14h,1h
9h-pyrido[3,4-b]indole, 1-methyl-
AB00052849
486-84-0
C09209
harman
harmane, 98%
NCGC00025022-06
NCGC00025022-03
KBIO3_001850
KBIO2_001606
KBIOSS_001606
KBIO1_001649
KBIO2_004174
KBIOGR_001465
KBIO2_006742
SPBIO_002779
SPECPLUS_000609
SPECTRUM3_000905
PRESTWICK1_000620
SPECTRUM4_001003
PRESTWICK0_000620
SPECTRUM1500866
NCGC00025022-05
NCGC00025022-04
NCGC00025022-02
smr000538681
MLS001173587
harmane, free base
H-1150
STK501254
NCGC00015514-04
H 7258
NCGC00015514-10
chebi:5623 ,
CHEMBL12014 ,
l-methylpyridobindole
1-methyl-2-carboline
cid_5281404
1-methyl-9h-beta-carboline (harman)
1-methyl-beta-carboline
bdbm50013786
AKOS002664659
HMS3261J12
harmane ( 1-methyl-9h-pyrido[3,4-b]indole)
CCG-204694
NCGC00015514-05
NCGC00015514-07
NCGC00015514-08
NCGC00015514-06
NCGC00015514-03
NCGC00015514-09
ST013856
methylbeta-carboline
HMS2858P09
5-23-08-00261 (beilstein handbook reference)
82d6j0535p ,
unii-82d6j0535p
FT-0626859
LP00605
harman [mi]
passiflorin-13c2,15n
SCHEMBL141723
tox21_500605
NCGC00261290-01
1-methyl-9h-pyrid(3,4-b)indole
1-methyl-9h-beta-carboline #
mfcd00004957
DTXSID80197568
passiflorine
zygofabagine
l-methyl-pyridobindole
1-methyl-9h-pyrido[3,4-b]indole, 9ci
SR-01000075915-1
SR-01000075915-7
SR-01000075915-8
sr-01000075915
CS-0021283
HB1665
HMS3676K19
1-methyl-9h-i(2)-carboline
AS-42735
HMS3412K19
Q15411006
AMY211
SDCCGSBI-0050587.P003
BCP31368
NCGC00015514-16
cyanoaceticacid-osu
HY-101392
cn9 ,
1-methyl-9h-pyrido[3,4-6]indole

Research Excerpts

Overview

Harmane (HA) is a β-carboline alkaloid derived from the Peganum harmala plant. Harmane is an active component of clonidine displacing substance and a candidate endogenous ligand for imidazoline binding sites.

ExcerptReferenceRelevance
"Harmane is a known tremorigenic β-carboline (a type of heterocyclic amine) found in cooked meat, roasted coffee beans, and tobacco."( From the Cover: Harmane-Induced Selective Dopaminergic Neurotoxicity in Caenorhabditis elegans.
Agim, ZS; Cannon, JR; Sammi, SR, 2018
)
1.55
"Harmane is an active component of clonidine displacing substance and a candidate endogenous ligand for imidazoline binding sites. "( Harmane: an atypical neurotransmitter?
Abu Ghazaleh, H; Hudson, AL; Lalies, MD; Nutt, DJ, 2015
)
3.3
"Harman is a common compound in several foods, plants and beverages. "( Harman induces CYP1A1 enzyme through an aryl hydrocarbon receptor mechanism.
El Gendy, MA; El-Kadi, AO, 2010
)
3.25
"Harmane (HA) is a β-carboline alkaloid derived from the Peganum harmala plant which induces memory impairment. "( Involvement of nitrergic system of CA1in harmane induced learning and memory deficits.
Abdollahian, M; Nasehi, M; Piri, M; Zarrindast, MR, 2013
)
2.1

Effects

nor-Harmane has never been used as a UV-MALDI matrix for the analysis of pectins but its use avoids pre-treatment of the sample, such as an enzymatic digestion or an acid hydrolysis. It is the most potent endogenous inhibitor of specific [3H]-flunitrazepam binding known so far.

ExcerptReferenceRelevance
"Harmane has also been shown to act on a variety of receptor systems in the mammalian brain, including those for serotonin, dopamine and benzodiazepines."( Involvement of dopamine D1/D2 receptors on harmane-induced amnesia in the step-down passive avoidance test.
Farzin, D; Nasehi, M; Nayer-Nouri, T; Nouri, M; Piri, M; Zarrindast, MR, 2010
)
1.34
"nor-Harmane has never been used as a UV-MALDI matrix for the analysis of pectins but its use avoids pre-treatment of the sample, such as an enzymatic digestion or an acid hydrolysis, and there is no need to add salts, making the analysis easier and faster."( Structural characterization of native high-methoxylated pectin using nuclear magnetic resonance spectroscopy and ultraviolet matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Comparative use of 2,5-dihydroxybenzoic acid and nor
Erra-Balsells, R; Kolender, AA; Monge, ME; Negri, RM, 2007
)
0.82
"Harmane has been previously found in rat brain and human urine, so it is the most potent endogenous inhibitor of specific [3H]-flunitrazepam binding known so far, with a several fold higher affinity for the benzodiazepine receptor than inosine and hypoxanthine."( 1-Methyl-beta-carboline (harmane), a potent endogenous inhibitor of benzodiazepine receptor binding.
Borbe, HO; Fehske, KJ; Müller, WE; Nanz, C; Rommelspacher, H; Wollert, U, 1980
)
1.29

Treatment

Harmane treatment decreased the retention latency significantly and dose dependently, which indicates an impairment in learning. Harman pretreatment (3-30 microM) also concentration dependently inhibited the contractions induced by phenylephrine, 5-hydroxytryptamine (5-HT), and KCl in endothelium-denuded aortic rings.

ExcerptReferenceRelevance
"Harmane treatment decreased the retention latency significantly and dose dependently, which indicates an impairment in learning."( Effect of harmane, an endogenous β-carboline, on learning and memory in rats.
Aricioglu, F; Celikyurt, IK; Gocmez, SS; Hudson, A; Utkan, T, 2013
)
1.51
"Harman pretreatment (3-30 microM) also concentration dependently inhibited the contractions induced by phenylephrine, 5-hydroxytryptamine (5-HT), and KCl in endothelium-denuded aortic rings in a non-competitive manner."( Vasorelaxant effect of harman.
Chen, CF; Chen, SY; Liao, JF; Shi, CC; Wang, GJ, 2000
)
1.34
"Harman treatment (27 nmol/hr) disturbed the regular rhythms at lower ethanol concentrations but mimicked the ultradian rhythm which was observed at high ethanol concentrations in CSF-treated animals."( Harman induces preference for ethanol in rats: is the effect specific for ethanol?
Büchau, C; Rommelspacher, H; Weiss, J, 1987
)
2.44
"Treatment with harmane had a profound anti-allodynic effect in a dose-dependent manner."( Effect of harmane on mononeuropathic pain in rats.
Aricioglu, F; Korcegez, E; Ozyalcin, S, 2003
)
1.06

Toxicity

ExcerptReferenceRelevance
" Histopathologically, rats fed 1,000 ppm harman or norharman, but not 500 ppm, demonstrated focal toxic renal degenerative/necrotic and regenerative lesions in proximal, distal, and collecting tubules."( Dose-dependent renal tubular toxicity of harman and norharman in male F344 rats.
Asakawa, E; Hagiwara, A; Hirose, M; Ito, N; Kurata, Y; Sano, M, 1992
)
0.82
" Although no toxicity-related hepatocyte lesions were found, severe renal toxic tubular lesions and regeneration were evident."( Lack of hepatotoxicity or promotion of enzyme-altered liver foci development in rats treated with harman or norharman.
Hagiwara, A; Ito, N; Kato, T; Kurata, Y; Tanaka, H; Tsuda, H, 1990
)
0.5
"Herbal medicines may have significant adverse effects which are not suspected or recognized."( Toxicity of Passiflora incarnata L.
Fisher, AA; Le Couteur, DG; Purcell, P, 2000
)
0.31
"Passiflora incarnata was associated with significant adverse effects in this patient."( Toxicity of Passiflora incarnata L.
Fisher, AA; Le Couteur, DG; Purcell, P, 2000
)
0.31
" These results suggest that neuromelanin has a critical role in HAA toxicity and adverse effects on mitochondria."( Neuromelanin formation exacerbates HAA-induced mitochondrial toxicity and mitophagy impairments.
Cannon, JR; Foguth, RM; Lawana, V; Um, SY, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" Objective This study investigates the dynamic metabolic profiles and pharmacokinetic properties of harmane and its metabolites in rats in vivo."( Pharmacokinetic study of harmane and its 10 metabolites in rat after intravenous and oral administration by UPLC-ESI-MS/MS.
Cheng, X; Jiang, B; Li, S; Liu, W; Teng, L; Wang, CH; Wang, Z, 2016
)
0.95

Compound-Compound Interactions

The present study was performed to investigate whether three amino compounds, 1-methyl-9H-pyrido[3,4-b]indole (harman) and 2-amino-1,3,.4-triazole (amitrole), might be converted in vivo to compounds capable of promoting hepatocarcinogenesis when given with NaNO(2)

ExcerptReferenceRelevance
" The present study was performed to investigate whether three amino compounds, 1-methyl-9H-pyrido[3,4-b]indole (harman), 9H-pyrido[3,4-b]indole (norharman) and 2-amino-1,3,4-triazole (amitrole), might be converted in vivo to compounds capable of promoting hepatocarcinogenesis when given with NaNO(2)."( Lack of combination hepatocarcinogenicity of harman, norharman and amitrole when given with NaNO2 in the rat.
Asamoto, M; Hirose, M; Ichihara, T; Imaida, K; Kawabe, M; Miyashita, K; Ogiso, T; Shirai, T; Tamano, S, 2005
)
0.8
" In order to know whether harmane is extensively metabolized, a rapid and sensitive method using ultra-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight tandem mass spectrometry (UPLC/ESI-QTOF-MS) was used to analyze the metabolic profile of harmane in vitro and in vivo in rats."( Metabolites identification of harmane in vitro/in vivo in rats by ultra-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight tandem mass spectrometry.
Cheng, X; Li, S; Liu, W; Teng, L; Wang, C; Wang, Z, 2014
)
0.99

Bioavailability

The absolute bioavailability of harmane following an oral dose was 19.5%. After an oral doses (20 mg/kg), theabsolute bioavailability (F) was 19% for harmani and 3% for harmine.

ExcerptReferenceRelevance
" After an oral dose (20 mg/kg), the absolute bioavailability (F) was 19% for harmane and 3% for harmine."( Toxicokinetics of tremorogenic natural products, harmane and harmine, in male Sprague-Dawley rats.
Guan, Y; Louis, ED; Zheng, W, 2001
)
0.79
" Studies on toxicokinetics indicate that inhalative exposure leads to a rapid increase in plasma levels and high bioavailability of norharman and harman."( Exposure to beta-carbolines norharman and harman.
Pfau, W; Skog, K, 2004
)
0.81
" Although bioavailability was variable depending on the source, a healthy diet contains amounts of quercetin that might give sufficient amounts in brain to induce, by monoamine oxidase A inhibition, a small decrease in neurotransmitter breakdown."( Dietary inhibitors of monoamine oxidase A.
Dixon Clarke, SE; Ramsay, RR, 2011
)
0.37
" The absolute bioavailability of harmane following an oral dose was 19."( Pharmacokinetic study of harmane and its 10 metabolites in rat after intravenous and oral administration by UPLC-ESI-MS/MS.
Cheng, X; Jiang, B; Li, S; Liu, W; Teng, L; Wang, CH; Wang, Z, 2016
)
1.02
" However, its physicochemical characteristics and poor oral bioavailability have been limiting factors for its pharmaceutical development."( Complexation with β-cyclodextrin enhances apoptosis-mediated cytotoxic effect of harman in chemoresistant BRAF-mutated melanoma cells.
Almeida, JRGDS; Beaugeard, L; de Alencar Filho, EB; de Oliveira Júnior, RG; de Oliveira, AP; Ferraz, CAA; Groult, H; Nunes, XP; Picot, L, 2020
)
0.78

Dosage Studied

ExcerptRelevanceReference
" beta CCE and beta CCtB produced dose-related, parallel shifts in the dose-response curve for the discriminative effects of diazepam, but the magnitude of the shifts was limited: the two highest doses of beta CCE and beta CCtB produced shifts that were not significantly different in magnitude."( Beta-carbolines as antagonists of the discriminative stimulus effects of diazepam in rats.
Cook, JA; Guzman, F; Hagen, TJ; Shannon, HE, 1988
)
0.27
" These findings indicate that harman affects the activity of mesolimbic dopaminergic neurons following a U-shaped dose-response relationship."( Harman-induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats.
Baum, SS; Hill, R; Rommelspacher, H, 1996
)
2.03
" On the other hand, concentrations in the micromolar range that are reached in high dosage animal experiments with HA may well influence cytochrome activity and, thus, influence the experimental outcome of these studies."( Modulation of cytochrome P450 1A1 by food-derived heterocyclic aromatic amines.
Hümmerich, J; Pfau, W; Zohm, C, 2004
)
0.32
" Dose-response curves were determined for phenylephrine and for several imidazoline ligands, using endothelium denuded, isolated ring segments, of tail arteries from adult male Sprague-Dawley rats."( Centrally acting imidazolines stimulate vascular alpha 1A-adrenergic receptors in Rat-Tail Artery.
Crane, L; Edwards, LP; George, OK; Gonzalez, RR; Kennedy, WB,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
anti-HIV agentAn antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
EC 1.4.3.4 (monoamine oxidase) inhibitorAn EC 1.4.3.* (oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor) inhibitor that interferes with the action of monoamine oxidase (EC 1.4.3.4).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
indole alkaloidAn alkaloid containing an indole skeleton.
indole alkaloid fundamental parent
harmala alkaloidAny member of a class of naturally occurring alkaloids based on a 1-methyl-9H-beta-carboline skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (65)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency31.73250.003245.467312,589.2998AID1705; AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency24.42740.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency24.42740.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency24.35200.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency23.66125.623417.292931.6228AID2323; AID485281
Chain A, CruzipainTrypanosoma cruziPotency32.46480.002014.677939.8107AID1476; AID1478
thioredoxin reductaseRattus norvegicus (Norway rat)Potency46.76900.100020.879379.4328AID488772; AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency9.19620.004110.890331.5287AID493107
NFKB1 protein, partialHomo sapiens (human)Potency1.99530.02827.055915.8489AID895; AID928
TDP1 proteinHomo sapiens (human)Potency22.36240.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency0.56230.180013.557439.8107AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.99210.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency25.11890.001318.074339.8107AID926; AID938
regulator of G-protein signaling 4Homo sapiens (human)Potency15.00300.531815.435837.6858AID504845
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency22.58880.001530.607315,848.9004AID1224819; AID1224820; AID1224821
Bloom syndrome protein isoform 1Homo sapiens (human)Potency19.95260.540617.639296.1227AID2364
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency17.20760.00207.533739.8107AID891
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency26.05290.001815.663839.8107AID894
mitogen-activated protein kinase 1Homo sapiens (human)Potency100.00000.039816.784239.8107AID995
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency3.98110.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency25.11890.00106.000935.4813AID943
lethal factor (plasmid)Bacillus anthracis str. A2012Potency1.99530.020010.786931.6228AID912
neuropeptide S receptor isoform AHomo sapiens (human)Potency5.01190.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency15.84890.316212.765731.6228AID881
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency15.84890.00638.235039.8107AID881
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piHomo sapiens (human)IC50 (µMol)12.30270.00011.02016.0000AID40988
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.507510.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Ki12.40000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)IC50 (µMol)12.30270.00011.02016.0000AID40988
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)20.91000.00000.94539.9400AID656680
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)IC50 (µMol)12.30270.00011.14948.0000AID40988
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.507510.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Ki12.40000.00020.656110.0000AID40666
Translocator proteinRattus norvegicus (Norway rat)IC50 (µMol)12.38800.00010.63934.8100AID40085
Gamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)IC50 (µMol)12.30270.00011.03936.0000AID40988
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.507510.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Ki12.40000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)IC50 (µMol)12.30270.00011.29158.0000AID40988
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.505710.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Ki12.40000.00020.561410.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.497310.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Ki12.40000.00020.635210.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.507510.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki12.40000.00020.621710.0000AID40666
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.498810.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Ki12.40000.00020.675810.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.504610.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki12.40000.00020.646910.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.507510.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki12.40000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)IC50 (µMol)12.30270.00011.30188.0000AID40988
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.507510.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Ki12.40000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.507510.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Ki12.40000.00020.671210.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)IC50 (µMol)12.30270.00010.98006.0000AID40988
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)IC50 (µMol)12.30270.00011.19936.0000AID40988
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)IC50 (µMol)12.30270.00011.02016.0000AID40988
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)IC50 (µMol)12.30270.00010.93746.0000AID40988
Gamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)IC50 (µMol)12.30270.00011.01936.0000AID40988
Tryptophan 2,3-dioxygenaseHomo sapiens (human)IC50 (µMol)6.31000.11001.66929.8000AID1886373
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.506510.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki12.40000.00020.557710.0000AID40666
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.505710.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Ki12.40000.00020.640310.0000AID40666
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.507510.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Ki12.40000.00020.570810.0000AID40666
Gamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)IC50 (µMol)12.30270.00011.02016.0000AID40988
Gamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)IC50 (µMol)12.30270.00011.02016.0000AID40988
Gamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)IC50 (µMol)12.30270.00011.02016.0000AID40988
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.507510.0000AID40085; AID40509; AID40514
GABA theta subunitRattus norvegicus (Norway rat)Ki12.40000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)IC50 (µMol)12.30270.00011.02016.0000AID40988
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)12.39200.00010.507510.0000AID40085; AID40509; AID40514
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Ki12.40000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)IC50 (µMol)12.30270.00011.02016.0000AID40988
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, BCL-2-RELATED PROTEIN A1Homo sapiens (human)EC50 (µMol)350.00008.0570121.1218338.0000AID2765
bcl-2-like protein 11 isoform 1Homo sapiens (human)EC50 (µMol)350.00008.0570121.1218338.0000AID2765
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA repair and recombination protein RAD54-like isoform 1Homo sapiens (human)AC5058.37000.814019.311978.9500AID651657
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (51)

Processvia Protein(s)Taxonomy
chloride transmembrane transportGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to toxic substanceGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
central nervous system neuron developmentGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to progesteroneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ovulation cycleGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
post-embryonic developmentGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
adult behaviorGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
roof of mouth developmentGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
behavioral fear responseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
associative learningGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
tryptophan catabolic process to kynurenineTryptophan 2,3-dioxygenaseHomo sapiens (human)
protein homotetramerizationTryptophan 2,3-dioxygenaseHomo sapiens (human)
response to nitroglycerinTryptophan 2,3-dioxygenaseHomo sapiens (human)
tryptophan catabolic process to acetyl-CoATryptophan 2,3-dioxygenaseHomo sapiens (human)
negative regulation of chloride transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
response to xenobiotic stimulusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
neurotransmitter transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (28)

Processvia Protein(s)Taxonomy
GABA-A receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
identical protein bindingGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signaling receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
tryptophan 2,3-dioxygenase activityTryptophan 2,3-dioxygenaseHomo sapiens (human)
protein bindingTryptophan 2,3-dioxygenaseHomo sapiens (human)
amino acid bindingTryptophan 2,3-dioxygenaseHomo sapiens (human)
oxygen bindingTryptophan 2,3-dioxygenaseHomo sapiens (human)
heme bindingTryptophan 2,3-dioxygenaseHomo sapiens (human)
identical protein bindingTryptophan 2,3-dioxygenaseHomo sapiens (human)
metal ion bindingTryptophan 2,3-dioxygenaseHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmembrane signaling receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter transmembrane transporter activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (36)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
apical plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
axonGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
nuclear envelopeGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
presynaptic active zone membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
Schaffer collateral - CA1 synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
nucleoplasmGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cytosolGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuronal cell body membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
presynaptic membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
extracellular exosomeGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
cytosolTryptophan 2,3-dioxygenaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
postsynaptic membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
cerebellar Golgi cell to granule cell synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
nucleolusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
microtubule cytoskeletonGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (200)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID435681Percentage MAPKAPK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID357034Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV12001Journal of natural products, Jul, Volume: 64, Issue:7
Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives.
AID435847Percentage DYRK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID423203Cytotoxicity against mouse P388 cells2009Journal of natural products, Apr, Volume: 72, Issue:4
5-Bromo-8-methoxy-1-methyl-beta-carboline, an alkaloid from the New Zealand marine bryozoan Pterocella vesiculosa.
AID435417Percentage PAK4 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1882205Antifungal activity against Alternaria solani relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Natural and synthetic β-carboline as a privileged antifungal scaffolds.
AID410367Cytotoxicity against human HeLa cells by MTT assay2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Synthesis and cytotoxic activities of 1-benzylidine substituted beta-carboline derivatives.
AID1882206Antifungal activity against Bipolaris maydis relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Natural and synthetic β-carboline as a privileged antifungal scaffolds.
AID656685Inhibition of human AChE at 10'-4 M by Ellman's method2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
AID103712In vitro cytotoxic activity against MCF-7 (human breast cancer) cell line.1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID435669Percentage PDK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID338147Antimicrobial activity against Bacillus subtilis assessed per disk
AID423205Antimicrobial activity against Candida albicans measured per disk2009Journal of natural products, Apr, Volume: 72, Issue:4
5-Bromo-8-methoxy-1-methyl-beta-carboline, an alkaloid from the New Zealand marine bryozoan Pterocella vesiculosa.
AID1882173Antifungal activity against Trichophyton interdigitale2022European journal of medicinal chemistry, Feb-05, Volume: 229Natural and synthetic β-carboline as a privileged antifungal scaffolds.
AID435706Percentage BRSK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435250Percentage MSK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID656680Inhibition of electric eel AChE using acetylcholine iodide as substrate measured every 5 sec for 2 mins by Ellman's method2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
AID473138Antiplatelet aggregation activity against collagen-induced platelet2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A class of 3S-2-aminoacyltetrahydro-beta-carboline-3-carboxylic acids: their facile synthesis, inhibition for platelet activation, and high in vivo anti-thrombotic potency.
AID435727Percentage JNK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1181717Antimicrobial activity against promastigote stage of Leishmania infantum2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
AID435373Percentage PKCzeta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435734Percentage NEK6 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID40514In vitro inhibition of 3[H]Diazepam binding to Benzodiazepine receptor from rat cerebral cortical membranes1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site.
AID300395Displacement of [3H]idazoxan from I2-imidazoline binding site in rabbit kidney membrane2007Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17
Synthesis of 3,8,9-trisubstituted-1,7,9-triaza-fluorene-6-carboxylic acid derivatives as a new class of insulin secretagogues.
AID1894518Inhibition of topoisomerase 1 (unknown origin) assessed as relaxation of pBR322 plasmid DNA and incubated for 10 mins2021European journal of medicinal chemistry, Apr-15, Volume: 216β-Carbolines as potential anticancer agents.
AID435865Percentage MKK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1632779Binding affinity to calf thymus duplex DNA assessed as red shift in soret peak at 50 uM in pH 7 phosphate buffer by UV-vis spectrophotometric analysis2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
DNA-binding studies of the natural β-carboline eudistomin U.
AID8467In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID435867Percentage NEK2a activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID300396Displacement of [3H]clonidine from alpha-2-adrenoceptor in cerebral cortex of rat brain2007Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17
Synthesis of 3,8,9-trisubstituted-1,7,9-triaza-fluorene-6-carboxylic acid derivatives as a new class of insulin secretagogues.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID410369Cytotoxicity against human BGC823 cells by MTT assay2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Synthesis and cytotoxic activities of 1-benzylidine substituted beta-carboline derivatives.
AID1478469Antiproliferative activity against human HL60 cells by tryphan blue assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Structurally Diverse Alkaloids from the Seeds of Peganum harmala.
AID1886370Inhibition of IDO1 (unknown origin) assessed as reduction in kynurenine production using L-tryptophan as substrate at 50 uM incubated for 1 hr by absorbance based microplate reader analysis relative to control2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Discovery of 1-(Hetero)aryl-β-carboline Derivatives as IDO1/TDO Dual Inhibitors with Antidepressant Activity.
AID558029Antiviral activity against JC polyomavirus M1/SVEdelta infected in human SVG-A cells assessed as inhibition of viral replication after 3 days2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID410370Cytotoxicity against human HepG2 cells by MTT assay2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Synthesis and cytotoxic activities of 1-benzylidine substituted beta-carboline derivatives.
AID435621Percentage p38alpha MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID338148Antimicrobial activity against Pseudomonas aeruginosa assessed per disk
AID338150Antimicrobial activity against Trichophyton mentagrophytes assessed per disk
AID357033Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication2001Journal of natural products, Jul, Volume: 64, Issue:7
Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives.
AID95653In vitro cytotoxic activity was determined against epidermoid carcinoma of the nasopharynx (KB) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID656681Inhibition of electric eel AChE using acetylcholine iodide as substrate at 10'-4 M measured every 5 sec for 2 mins by Ellman's method2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
AID435350Percentage ERK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435338Percentage CaMK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435854Percentage IKK-beta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1529815Antibacterial activity against Staphylococcus aureus after 18 hrs2018European journal of medicinal chemistry, Dec-05, Volume: 160Design, synthesis and biological evaluations of quaternization harman analogues as potential antibacterial agents.
AID1194597Inhibition of PTP1B (unknown origin) assessed as inhibition rate at 100 uM2015Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9
Canthinone alkaloids are novel protein tyrosine phosphatase 1B inhibitors.
AID338149Antimicrobial activity against Candida albicans assessed per disk
AID1226062Mitochondrial uncoupling activity in HEK293T/17 cells at 50 uM after 30 mins by TMRE staining-based fluorescence assay2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Exploiting the Polypharmacology of ß-Carbolines to Disrupt O. volvulus Molting.
AID435375Percentage RSK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435728Percentage JNK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436036Percentage Lck activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID338121Cytotoxicity against mouse P388 cells
AID625776Antiplatelet activity in rabbit platelets assessed as inhibition of collagen-induced platelet aggregation2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
A class of novel N-(1-methyl-β-carboline-3-carbonyl)-N'-(aminoacid-acyl)-hydrazines: aromatization leaded design, synthesis, in vitro anti-platelet aggregation/in vivo anti-thrombotic evaluation and 3D QSAR analysis.
AID94194In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-VIN (expressing P-glycoprotein)1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID1632799Binding affinity to calf thymus duplex DNA assessed as induction of ellipticity at 350 nanometer at 25 to 200 uM in pH 7 phosphate buffer by circular dichroism method2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
DNA-binding studies of the natural β-carboline eudistomin U.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID436071Percentage CHK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435814Percentage PIM3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID343385Inhibition of Trypanosoma cruzi recombinant trypanothione reductase at 85 uM2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID435123Percentage NEK7 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID435979Percentage MST2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID357032Cytotoxicity against human H9 cells2001Journal of natural products, Jul, Volume: 64, Issue:7
Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives.
AID338124Antiviral activity against Herpes simplex virus (type 1 / strain F) ATCC VR 733 in african green monkey BSC1 cells assessed as excess radius from disk edge at 20 ug/disk
AID40509Binding affinity towards benzodiazepine receptor inverse agonist site by the displacement of [3H]diazepam in rat cerebral cortical membranes.1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
AID396084Displacement of [3H]diazepam from benzodiazepine receptor in rat brain2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
3D and quantum QSAR of non-benzodiazepine compounds.
AID435539Percentage PHK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID82702In vitro cytotoxic activity was determined against embryonic lung fibroblast (HEL) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID338141Cytotoxicity against african green monkey BSC1 cells at 20 ug/disk
AID55536Percentage inhibition against cyclin dependent kinase 5 (CDK 5) at a concentration of 50 uM2002Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
Beta-carbolines as specific inhibitors of cyclin-dependent kinases.
AID300391Effect on glucose-dependent insulin secretion activity per ug of total protein in rat RIN5F cells at 0.1 uM after 30 mins2007Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17
Synthesis of 3,8,9-trisubstituted-1,7,9-triaza-fluorene-6-carboxylic acid derivatives as a new class of insulin secretagogues.
AID435819Percentage PKBbeta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435718Percentage EF2K activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435300Percentage PAK6 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID435256Percentage p38-gamma MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436072Percentage CK1delta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436083Percentage ERK8 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID338151Antimicrobial activity against Cladosporium resinae assessed per disk
AID40988Inhibition on Benzodiazepine receptor1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications.
AID1882176Antifungal activity against Candida albicans incubated for 72 hrs2022European journal of medicinal chemistry, Feb-05, Volume: 229Natural and synthetic β-carboline as a privileged antifungal scaffolds.
AID300394Displacement of [3H]clonidine from I1-imidazoline binding site in bovine adrenal medulla plasma membrane2007Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17
Synthesis of 3,8,9-trisubstituted-1,7,9-triaza-fluorene-6-carboxylic acid derivatives as a new class of insulin secretagogues.
AID656684Inhibition of human AChE by Ellman's method2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
AID435713Percentage CHK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435339Percentage CaMKKbeta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435374Percentage PLK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID300392Effect on glucose-dependent insulin secretion activity per ug of total protein in rat RIN5F cells at 1 uM after 30 mins2007Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17
Synthesis of 3,8,9-trisubstituted-1,7,9-triaza-fluorene-6-carboxylic acid derivatives as a new class of insulin secretagogues.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID435995Percentage SRPK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435747Percentage PRAK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435228Percentage ERK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID40666In vitro inhibition of [3H]diazepam binding to benzodiazepine receptor in rat cerebral cortical membrane1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Beta-carbolines: synthesis and neurochemical and pharmacological actions on brain benzodiazepine receptors.
AID435418Percentage PAK5 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID94188In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-CPT (pleotrophic mechanism including level of topoisomerase I)1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID435541Percentage PKA activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435756Percentage Src activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID201791In vitro cytotoxic activity was determined against melanoma cancer (SK-MEL-2) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID435820Percentage PKCalpha activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1181720Antimicrobial activity against promastigote stage of Leishmania donovani after 72 hrs by Alamar Blue assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
AID435842Percentage Aurora C activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435613Percentage MNK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID423206Antimicrobial activity against Trichophyton mentagrophytes measured per disk2009Journal of natural products, Apr, Volume: 72, Issue:4
5-Bromo-8-methoxy-1-methyl-beta-carboline, an alkaloid from the New Zealand marine bryozoan Pterocella vesiculosa.
AID435363Percentage MELK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435987Percentage PRK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435881Percentage ROCK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID558036Therapeutic index, ratio of TC50 for JC polyomavirus M1/SVEdelta infected human SVG-A cells to EC50 for JC polyomavirus M1/SVEdelta2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID300393Effect on glucose-dependent insulin secretion activity per ug of total protein in rat RIN5F cells at 10 uM after 30 mins2007Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17
Synthesis of 3,8,9-trisubstituted-1,7,9-triaza-fluorene-6-carboxylic acid derivatives as a new class of insulin secretagogues.
AID435225Percentage DYRK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID213899In vitro cytotoxic activity against U-87-MG (glioblastoma) cell line.1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID410368Cytotoxicity against human Bel7402 cells by MTT assay2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Synthesis and cytotoxic activities of 1-benzylidine substituted beta-carboline derivatives.
AID435370Percentage p38beta MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1226063Antionchocerciasis activity against L3 larval stage of Onchocerca volvulus assessed as inhibition of parasite molting at 10 uM treated for 24 hrs prior to complete medium and PBMC addition measured after 6 days by inverted microscopic analysis2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Exploiting the Polypharmacology of ß-Carbolines to Disrupt O. volvulus Molting.
AID1886373Inhibition of TDO (unknown origin) assessed as reduction in N-formylkynurenine formation using L-tryptophan as substrate incubated for 75 mins by UV absorbance based analysis2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Discovery of 1-(Hetero)aryl-β-carboline Derivatives as IDO1/TDO Dual Inhibitors with Antidepressant Activity.
AID435704Percentage Aurora B activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1886372Inhibition of TDO (unknown origin) assessed as reduction in N-formylkynurenine formation using L-tryptophan as substrate at 50 uM incubated for 75 mins by UV absorbance based analysis relative to control2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Discovery of 1-(Hetero)aryl-β-carboline Derivatives as IDO1/TDO Dual Inhibitors with Antidepressant Activity.
AID1632787Binding affinity to calf thymus duplex DNA assessed as change in melting temperature at 50 uM in pH 7 phosphate buffer by UV-vis spectrophotometric analysis2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
DNA-binding studies of the natural β-carboline eudistomin U.
AID94013In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-7d (pleotrophic resistance including MRP multidrug resistant protein)1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID1478471Antiproliferative activity against human SGC7901 cells by MTT assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Structurally Diverse Alkaloids from the Seeds of Peganum harmala.
AID435233Percentage HIPK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435962Percentage CDK2-cyclinA activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435260Percentage RSK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435731Percentage MNK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID42569In vitro cytotoxic activity was determined against renal cancer (CAKI-1) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID435738Percentage p38delta MAPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID348954Displacement of [3H]diazepam from GABAA/BzR in rat brain membrane2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
Quantitative structure-activity relationship studies of a series of non-benzodiazepine structural ligands binding to benzodiazepine receptor.
AID435176Percentage PIM2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435454Percentage CaMKKalpha activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID55535Percentage inhibition against cyclin dependent kinase 2 (CDK 2) at a concentration of 50 uM2002Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
Beta-carbolines as specific inhibitors of cyclin-dependent kinases.
AID2964In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs.
AID435493Percentage PKD1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID338132Antiviral activity against Polio virus 1 Pfizer vaccine in african green monkey BSC1 cells assessed as excess radius from disk edge at 20 ug/disk
AID1181716Antimicrobial activity against amastigote stage of Leishmania infantum2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID423204Antimicrobial activity against Bacillus subtilis measured per disk2009Journal of natural products, Apr, Volume: 72, Issue:4
5-Bromo-8-methoxy-1-methyl-beta-carboline, an alkaloid from the New Zealand marine bryozoan Pterocella vesiculosa.
AID435501Percentage SmMLCK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435427Percentage PKBalpha activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436086Percentage HIPK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1632781Binding affinity to calf thymus duplex DNA assessed as induction of hyperchromic shift at 257 nanometer at 50 uM in pH 7 phosphate buffer by UV-vis spectrophotometric analysis2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
DNA-binding studies of the natural β-carboline eudistomin U.
AID40085Binding affinity for rat benzodiazepine receptor inverse agonist site1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID453268Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D62009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID435378Percentage S6K1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID558037Cytotoxicity against human SVG-A cells2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID1226058Inhibition of L3 larval stage of Onchocerca volvulus chitinase using 4-methylumbelliferyl-N-N'-N''-beta-chitotrioside as substrate assessed as release of 4-methylumbelliferone measured for 10 mins by fluorescence assay2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Exploiting the Polypharmacology of ß-Carbolines to Disrupt O. volvulus Molting.
AID1478470Antiproliferative activity against human PC3 cells by MTT assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Structurally Diverse Alkaloids from the Seeds of Peganum harmala.
AID435223Percentage CSK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435461Percentage CK2 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435215Percentage AMPK activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID338146Antimicrobial activity against Escherichia coli assessed per disk
AID1181721Antimicrobial activity against axenic amastigote stage of Leishmania donovani after 72 hrs by Alamar Blue assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
AID435723Percentage GSK3-beta activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID1632804Binding affinity to calf thymus duplex DNA assessed as melting temperature at 0.5 mM by differential scanning calorimetry (Rvb = 51 degC)2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
DNA-binding studies of the natural β-carboline eudistomin U.
AID453269Antimalarial activity against chloroquine-resistant Plasmodium falciparum W22009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID1226064Antionchocerciasis activity against L3 larval stage of Onchocerca volvulus assessed as prevention of L3 cuticle shedding at 100 uM treated for 24 hrs prior to complete medium and PBMC addition measured after 6 days by inverted microscopic analysis2015ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3
Exploiting the Polypharmacology of ß-Carbolines to Disrupt O. volvulus Molting.
AID436076Percentage DYRK1A activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435317Percentage PIM1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435883Percentage SGK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435238Percentage JNK1 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID436037Percentage MAPKAPK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID435315Percentage MARK3 activity remaining in the presence of 1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
The selectivity of protein kinase inhibitors: a further update.
AID453270Cytotoxicity in human THP1 cells2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID1713264Antileishmanial activity against late log phase promastigote stage of Leishmania infantum MHOM/FR/78/LEM75 assessed as inhibition of parasite growth incubated for 48 hrs by hemocytometer counting method2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and anti-leishmanial evaluation of 1-phenyl-2,3,4,9-tetrahydro-1H-β-carboline derivatives against Leishmania infantum.
AID125789Inhibitory effect on Bufuralol 1'-hydroxylation by human liver microsomes (Ki = apparent inhibition constant)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (295)

TimeframeStudies, This Drug (%)All Drugs %
pre-199050 (16.95)18.7374
1990's47 (15.93)18.2507
2000's90 (30.51)29.6817
2010's85 (28.81)24.3611
2020's23 (7.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 78.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index78.02 (24.57)
Research Supply Index5.76 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index252.14 (26.88)
Search Engine Supply Index3.67 (0.95)

This Compound (78.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.96%)5.53%
Reviews16 (5.13%)6.00%
Case Studies1 (0.32%)4.05%
Observational0 (0.00%)0.25%
Other292 (93.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]